Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Cash from Operations (2024 - 2025)

Historic Cash from Operations for Kura Oncology (KURA) over the last 2 years, with Q3 2025 value amounting to -$80.6 million.

  • Kura Oncology's Cash from Operations fell 8560.54% to -$80.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.8 million, marking a year-over-year change of. This contributed to the annual value of $134.3 million for FY2024, which is 20760.51% up from last year.
  • As of Q3 2025, Kura Oncology's Cash from Operations stood at -$80.6 million, which was down 8560.54% from -$28.8 million recorded in Q2 2025.
  • Kura Oncology's Cash from Operations' 5-year high stood at $269.1 million during Q4 2024, with a 5-year trough of -$80.6 million in Q3 2025.